Cytokinetics Inc (CYTK)
66.82
+1.25
(+1.91%)
USD |
NASDAQ |
Apr 24, 16:00
66.82
0.00 (0.00%)
Pre-Market: 20:00
Cytokinetics Enterprise Value: 6.885B for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 6.885B |
| April 23, 2024 | 6.757B |
| April 22, 2024 | 6.831B |
| April 19, 2024 | 6.961B |
| April 18, 2024 | 6.904B |
| April 17, 2024 | 7.000B |
| April 16, 2024 | 7.110B |
| April 15, 2024 | 7.007B |
| April 12, 2024 | 7.374B |
| April 11, 2024 | 7.542B |
| April 10, 2024 | 7.662B |
| April 09, 2024 | 7.733B |
| April 08, 2024 | 7.645B |
| April 05, 2024 | 7.492B |
| April 04, 2024 | 7.128B |
| April 03, 2024 | 7.308B |
| April 02, 2024 | 7.313B |
| April 01, 2024 | 7.524B |
| March 28, 2024 | 7.224B |
| March 27, 2024 | 7.358B |
| March 26, 2024 | 7.331B |
| March 25, 2024 | 7.082B |
| March 22, 2024 | 6.947B |
| March 21, 2024 | 6.804B |
| March 20, 2024 | 6.941B |
| Date | Value |
|---|---|
| March 19, 2024 | 6.965B |
| March 18, 2024 | 6.569B |
| March 15, 2024 | 6.718B |
| March 14, 2024 | 6.569B |
| March 13, 2024 | 6.660B |
| March 12, 2024 | 6.652B |
| March 11, 2024 | 6.635B |
| March 08, 2024 | 6.775B |
| March 07, 2024 | 6.784B |
| March 06, 2024 | 6.892B |
| March 05, 2024 | 6.845B |
| March 04, 2024 | 6.974B |
| March 01, 2024 | 7.623B |
| February 29, 2024 | 7.444B |
| February 28, 2024 | 7.531B |
| February 27, 2024 | 8.345B |
| February 26, 2024 | 8.032B |
| February 23, 2024 | 7.932B |
| February 22, 2024 | 7.685B |
| February 21, 2024 | 7.778B |
| February 20, 2024 | 7.818B |
| February 16, 2024 | 7.818B |
| February 15, 2024 | 7.987B |
| February 14, 2024 | 7.778B |
| February 13, 2024 | 7.832B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
346.21M
Minimum
May 01 2019
10.99B
Maximum
Jan 08 2024
2.535B
Average
2.582B
Median
May 09 2022
Enterprise Value Benchmarks
| Amgen Inc | 199.98B |
| Johnson & Johnson | 364.33B |
| Eli Lilly and Co | 718.54B |
| Viking Therapeutics Inc | 6.177B |
| Madrigal Pharmaceuticals Inc | 3.553B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -136.90M |
| Revenue (Quarterly) | 1.672M |
| Total Expenses (Quarterly) | 129.09M |
| EPS Diluted (Quarterly) | -1.38 |
| Gross Profit Margin (Quarterly) | -4.98K% |
| Profit Margin (Quarterly) | -8.19K% |
| Earnings Yield | -8.16% |
| Normalized Earnings Yield | -8.156 |